Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriella Parma

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
The Oncologist|December 14, 2024
Safety and quality of life with maintenance olaparib plus bevacizumab in older patients with ovarian cancer: subgroup analysis of PAOLA‑1/ENGOT-ov25Coline Montégut, Claire Falandry, Saverio Cinieri, et al.
Archives of Pathology & Laboratory Medicine|December 8, 2024
Can Morphology and Immune Infiltration Predict the Homologous Recombination Deficiency Status in Newly Diagnosed High-Grade Serous Ovarian Carcinoma?Amel Kime, Guillaume Bataillon, Isabelle Treilleux, et al.
European Journal of Cancer (Oxford, England : 1990)|April 8, 2026
Rational adjustment of dose to reduce adverse reactions (RADAR) in patients with platinum-sensitive recurrent ovarian cancer: Results from the phase II NEWTON trial (ENGOT-ov49)Nicoletta Colombo, Gabriella Parma, Giulia Tasca, et al.
The Lancet. Oncology|August 5, 2024
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trialNicoletta Colombo, Elena Biagioli, Kenichi Harano, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trialDomenica Lorusso, Marie-Ange Mouret-Reynier, Philipp Harter, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 21, 2023
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trialDomenica Lorusso, Marie-Ange Mouret-Reynier, Philipp Harter, et al.
Lancet (London, England)|April 13, 2026
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 studyNicoletta Colombo, Emese Zsiros, Gabriella Parma, et al.
Journal of the National Cancer Institute|April 25, 2026
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25)Florence Joly, Amélie Anota, Sylvie Chabaud, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
The Oncologist|December 14, 2024
Safety and quality of life with maintenance olaparib plus bevacizumab in older patients with ovarian cancer: subgroup analysis of PAOLA‑1/ENGOT-ov25Coline Montégut, Claire Falandry, Saverio Cinieri, et al.
Archives of Pathology & Laboratory Medicine|December 8, 2024
Can Morphology and Immune Infiltration Predict the Homologous Recombination Deficiency Status in Newly Diagnosed High-Grade Serous Ovarian Carcinoma?Amel Kime, Guillaume Bataillon, Isabelle Treilleux, et al.
European Journal of Cancer (Oxford, England : 1990)|April 8, 2026
Rational adjustment of dose to reduce adverse reactions (RADAR) in patients with platinum-sensitive recurrent ovarian cancer: Results from the phase II NEWTON trial (ENGOT-ov49)Nicoletta Colombo, Gabriella Parma, Giulia Tasca, et al.
The Lancet. Oncology|August 5, 2024
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trialNicoletta Colombo, Elena Biagioli, Kenichi Harano, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trialDomenica Lorusso, Marie-Ange Mouret-Reynier, Philipp Harter, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 21, 2023
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trialDomenica Lorusso, Marie-Ange Mouret-Reynier, Philipp Harter, et al.
Lancet (London, England)|April 13, 2026
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 studyNicoletta Colombo, Emese Zsiros, Gabriella Parma, et al.
Journal of the National Cancer Institute|April 25, 2026
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25)Florence Joly, Amélie Anota, Sylvie Chabaud, et al.
Pageof 3